Immuneering (IMRX) Cash & Equivalents (2020 - 2026)

Immuneering's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 31.94% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 31.94% YoY), while the FY2025 annual figure was $128.6 million, up 255.92% from the prior year.
• Cash & Equivalents was $47.3 million for Q1 2026 at Immuneering, down from $128.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $227.6 million in Q3 2025 to a low of $26.4 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $76.1 million across 5 years, with a median of $68.0 million in 2023.
• Biggest YoY gain for Cash & Equivalents was 403.4% in 2025; the steepest drop was 55.87% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $72.6 million in 2022, then dropped by 18.22% to $59.4 million in 2023, then slumped by 39.16% to $36.1 million in 2024, then soared by 255.92% to $128.6 million in 2025, then plunged by 63.22% to $47.3 million in 2026.
• The last three Cash & Equivalents figures came in at $47.3 million (Q1 2026), $128.6 million (Q4 2025), and $227.6 million (Q3 2025), per Business Quant data.